Entrada Therapeutics (TRDA) Total Current Liabilities (2022 - 2025)
Historic Total Current Liabilities for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $24.0 million.
- Entrada Therapeutics' Total Current Liabilities fell 6598.02% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.0 million, marking a year-over-year decrease of 6598.02%. This contributed to the annual value of $39.5 million for FY2024, which is 7513.67% down from last year.
- Entrada Therapeutics' Total Current Liabilities amounted to $24.0 million in Q3 2025, which was down 6598.02% from $19.8 million recorded in Q2 2025.
- Entrada Therapeutics' 5-year Total Current Liabilities high stood at $173.9 million for Q1 2024, and its period low was $15.4 million during Q1 2022.
- In the last 4 years, Entrada Therapeutics' Total Current Liabilities had a median value of $39.5 million in 2024 and averaged $73.8 million.
- In the last 5 years, Entrada Therapeutics' Total Current Liabilities skyrocketed by 85678.72% in 2023 and then plummeted by 8940.37% in 2025.
- Entrada Therapeutics' Total Current Liabilities (Quarter) stood at $22.0 million in 2022, then surged by 622.72% to $158.8 million in 2023, then crashed by 75.14% to $39.5 million in 2024, then tumbled by 39.16% to $24.0 million in 2025.
- Its Total Current Liabilities stands at $24.0 million for Q3 2025, versus $19.8 million for Q2 2025 and $18.4 million for Q1 2025.